- Key Takeaways:
- China proposes allowing drug reimbursement applications before final approval.
- The new rules could shorten the gap between approval and sales by 1-2 years.
- A new link to commercial insurance may help high-priced drugs gain access.
Back
China's New Draft Drug Policy Could Cut 1-2 Years Off Wait Times
China's new draft drug reimbursement policy is poised to cut the time-to-market for innovative drugs by one to two years, a move expected to boost revenue for pharmaceutical firms and their partners.
The reforms will "further improve the commercialization outlook for innovative drug developers in China and their CXO partners," JPMorgan analysts said in a research report.
The draft plan from the National Healthcare Security Administration introduces two major changes for the 2026 National Reimbursement Drug List (NRDL). First, it allows companies to apply for reimbursement listing before a drug receives formal market approval, a change JPMorgan notes could significantly shorten the historical one- to two-year lag between approval and inclusion.
Second, the plan establishes a formal link between the NRDL and commercial health insurance. This creates a "commercial insurance first, NRDL follow-up" pathway, opening a new door for higher-priced innovative drugs that previously struggled to enter the reimbursement list due to pricing constraints.
The changes are a direct catalyst for drugmakers with assets in or near the final stages of regulatory review, as earlier NRDL inclusion means a faster sales ramp-up and clearer revenue visibility. The new dual-list strategy also benefits drugs already covered by commercial insurance that were previously considered too expensive for the national plan.
JPMorgan reiterated its positive view on the sector, naming Innovent Biologics (01801.HK), SKB BIO (06990.HK), WuXi AppTec (02359.HK), and WuXi XDC (02268.HK) as its top picks to benefit from the accelerated commercialization.
The policy shift signals a clear government priority to support pharmaceutical innovation and improve patient access to new treatments. Investors will now watch for the final version of the plan and which companies are first to use the new pre-approval application pathway in 2026.
This article is for informational purposes only and does not constitute investment advice.
[1] JPMorgan Research: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO (01801.HK), WUXI APPTEC (02359.HK), WUXI XDC (02268.HK), SKB BIO (06990.HK)[2] China outlines legislative priorities for 2026[3] China knows that governing new tech can be harder than inventing it[4] China wants more robots but not fewer workers[5] GSK plans to sell chronic hepatitis B drug in China through Sino Biopharm
